Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 11;7(13):3225-3231.
doi: 10.1182/bloodadvances.2022009323.

Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma

Christopher J Forlenza  1 , Jaclyn Rosenzweig  1 , Audrey Mauguen  2 , Ilia Buhtoiarov  3 , Branko Cuglievan  4 , Hema Dave  5 , Rebecca J Deyell  6 , Jamie E Flerlage  7 , Anna K Franklin  8 , Jennifer Krajewski  9 , Kasey J Leger  10 , Lianna J Marks  11 , Robin E Norris  12 , Martha Pacheco  13 , Faye Willen  14 , Adam Paul Yan  15   16 , Paul D Harker-Murray  17 , Lisa Giulino-Roth  18
Affiliations

Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma

Christopher J Forlenza et al. Blood Adv. .

Abstract

Outcomes for children and adolescents with relapsed and refractory Hodgkin lymphoma (HL) are poor, with ∼50% of patients experiencing a subsequent relapse. The anti-CD30 antibody-drug conjugate brentuximab vedotin improved progression-free survival (PFS) when used as consolidation after autologous stem cell transplantation (ASCT) in adults with high-risk relapsed/refractory HL. Data on brentuximab vedotin as consolidative therapy after ASCT in pediatric patients with HL are extremely limited, with data of only 11 patients reported in the literature. We performed a retrospective analysis of 67 pediatric patients who received brentuximab vedotin as consolidation therapy after ASCT for the treatment of relapsed/refractory HL to describe the experience of this regimen in the pediatric population. This is the largest cohort reported to date. We found that brentuximab vedotin was well tolerated with a safety profile similar to that of adult patients. With a median follow-up of 37 months, the 3-year PFS was 85%. These data suggest a potential role for the use of brentuximab vedotin as consolidation therapy after ASCT for children with relapsed/refractory HL.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: K.J.L. reports consulting or advisory roles at Jazz Pharmaceuticals and research funding from Abbott Diagnostics. L.G.-R. reports consulting roles at Janssen and Merck. C.J.F., J.R., I.B., B.C., H.D., R.J.D., and J.E.F. received clinical trial support from Seattle Genetics. The remaining authors declare no competing financial interests.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Overall survival and PFS. (A) Overall survival and PFS in all patients (B) PFS based on pretransplantation–brentuximab vedotin exposure; PFS includes 95% CI.
See this image and copyright information in PMC

References

    1. Daw S, Wynn R, Wallace H. Management of relapsed and refractory classical Hodgkin lymphoma in children and adolescents. Br J Haematol. 2011;152(3):249–260. - PubMed
    1. Friedman DL, Chen L, Wolden S, et al. Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk Hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031. J Clin Oncol. 2014;32(32):3651–3658. - PMC - PubMed
    1. Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood. 2009;114(10):2051–2059. - PMC - PubMed
    1. Lieskovsky YE, Donaldson SS, Torres MA, et al. High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: results and prognostic indices. J Clin Oncol. 2004;22(22):4532–4540. - PubMed
    1. Claviez A, Kabisch H, Suttorp M, et al. The impact of disease status at transplant and time to first relapse on outcome in children and adolescents with Hodgkin’s lymphoma undergoing autologous stem cell transplantation. Blood. 2004;104(11):1878.

Publication types

Substances